NeuroBo Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public, Subsidiary

Established: 2014-01-01

Employees: 8

Market Cap: -

Website: http://www.neurobopharma.com

Introduction: NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Cambridge, MA.

Clinical Trials

First in Human Study in Subjects With Obesity, But Otherwise Healthy

Phase 1

Recruiting

Conditions: Obesity

Interventions: Drug: DA-1726
Drug: Placebo to DA-1726

First Posted Date: 2024-02-09

Last Posted Date: 2025-05-21

Lead Sponsor: NeuroBo Pharmaceuticals Inc.

Target Recruit Count: 81

Registration Number: NCT06252220

Locations: 🇺🇸
Clinical Pharmacology of Miami, LLC, Miami, Florida, United States

Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH

Phase 2

Completed

Conditions: NON-ALCOHOLIC STEATOHEPATITIS

Interventions: Drug: DA-1241
Drug: Sitagliptin Placebo
Drug: DA-1241 Placebo
Drug: Sitagliptin

First Posted Date: 2023-09-26

Last Posted Date: 2024-11-14

Lead Sponsor: NeuroBo Pharmaceuticals Inc.

Target Recruit Count: 109

Registration Number: NCT06054815

Locations: 🇺🇸
Southern California Research Center, Coronado, California, United States
🇺🇸
Catalina Research Institute, LLC, Montclair, California, United States
🇺🇸
Velocity Clinical Research, Panorama City, Panorama City, California, United States

and more 15 locations

A Single and Multiple Ascending Dose Study of Niclosamide in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Niclosamide
Drug: Placebo

First Posted Date: 2021-01-12

Last Posted Date: 2025-02-03

Lead Sponsor: NeuroBo Pharmaceuticals Inc.

Target Recruit Count: 54

Registration Number: NCT04705415

Locations: 🇺🇸
WCCT Global Inc., Cypress, California, United States

Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients

Phase 2

Completed

Conditions: COVID-19

Interventions: Drug: Niclosamide
Drug: Placebo

First Posted Date: 2020-10-27

Last Posted Date: 2025-05-15

Lead Sponsor: NeuroBo Pharmaceuticals Inc.

Target Recruit Count: 49

Registration Number: NCT04603924

Locations: 🇺🇸
Baptist Health Research Institute, Jacksonville, Florida, United States
🇺🇸
University of California, Irvine, Irvine, California, United States
🇺🇸
AdventHealth Tampa, Tampa, Florida, United States

and more 5 locations

A 12-Week Study to Assess the Efficacy Safety and Tolerability of Gemcabene in Subjects With Severe Hypertriglyceridemia

Phase 2

Completed

Conditions: Severe Hypertriglyceridemia
Mixed Dyslipidaemia

Interventions: Drug: Placebo
Drug: Gemcabene

First Posted Date: 2016-10-25

Last Posted Date: 2020-06-25

Lead Sponsor: NeuroBo Pharmaceuticals Inc.

Target Recruit Count: 91

Registration Number: NCT02944383

Locations: 🇺🇸
Soma Medical Research, West Palm Beach, Florida, United States
🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸
Physicians East, NA, Greenville, North Carolina, United States

and more 43 locations

Efficacy and Safety of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid-Lowering Therapy (COBALT-1)

Phase 2

Completed

Conditions: Hypercholesteremia

Interventions: Drug: Gemcabene

First Posted Date: 2016-03-30

Last Posted Date: 2020-06-25

Lead Sponsor: NeuroBo Pharmaceuticals Inc.

Target Recruit Count: 8

Registration Number: NCT02722408

Locations: 🇨🇦
Robarts Research Institute, London, Ontario, Canada
🇺🇸
Westside Medical Associates of Los Angeles, Beverly Hills, California, United States
🇮🇱
Wolfson Medical Center Internal Medicine Dept., Holon, Israel

and more 4 locations

A 12-Week, Phase 2 Study of Gemcabene in Hypercholesterolemia Patients on Stable Moderate and High-Intensity Statins

Phase 2

Completed

Conditions: Hypercholesteremia

Interventions: Drug: Placebo
Drug: Gemcabene

First Posted Date: 2015-12-17

Last Posted Date: 2020-06-25

Lead Sponsor: NeuroBo Pharmaceuticals Inc.

Target Recruit Count: 105

Registration Number: NCT02634151

Locations: 🇺🇸
Westside Medical Associates of Los Angeles, Beverly Hills, California, United States
🇺🇸
Atlantic Clinical Research Collaborative- Cardiology, Atlantis, Florida, United States
🇺🇸
Progressive Medical Research, Port Orange, Florida, United States

and more 18 locations